CClinicalTrials.gg
CompletedNCT05369819Updated Jan 5, 2024

Effect of Midazolam Premedication on Opioid-induced Mask Ventilation Difficulty

A Phase 4 interventional study of Midazolam and Saline in Anesthesia Complication, sponsored by Karaman Training and Research Hospital. Completed at 1 site in Turkey. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-01-05.

Sponsored by Karaman Training and Research Hospital · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Mask ventilation has great importance during anesthesia induction because it is the only way to oxygenate patients who have lost consciousness and spontaneous breathing. Opioid-derived drugs used in anesthesia induction may cause difficulty in mask ventilation due to their chest wall rigidity and respiratory depressant effects. Adequate muscle relaxation and depth of anesthesia may assist with mask ventilation. It is known that premedication reduces anxiety and has a relaxing effect on airway muscles. Midazolam is frequently used in premedication because it has a rapid onset of action and does not cause hemodynamic changes. In addition, midazolam may relax the airway by acting directly on the airway smooth muscle and thus facilitate mask ventilation during anesthesia induction. In this study, the investigators will evaluate the effect of midazolam premedication on the mask ventilation after induction with remifentanil.

Read the detailed description

American Society of Anesthesiologists (ASA) class I and II patients who are admitted to undergoing elective surgery under general anesthesia will be enrolled. Patients in midazolam group (Group M) will be treated with midazolam premedication (3 cc mixture of 0.035 mg/kg midazolam and normal saline; maximum midazolam dose, 3 mg) intravenously in a waiting area 3 minutes before transportation to an operating room, while 3 cc normal saline will be administered to control group (Group S) patients. The difficulty of mask ventilation will be evaluated before the injection of neuromuscular blocking during general anesthetic induction. The anxiety and sedation levels of patients will be estimated before the intervention and before anesthetic induction in an operating room. Remifentanil will be used as an opioid in the induction of the patients. In anesthesia induction, propofol 1.5 mg/kg will be given after remifentanil is infused at a dose of 0.30 µg/kg/min for three minutes. Before the patients were given muscle relaxants, the patients were evaluated with the Warter scale

02

Conditions studied

  • Anesthesia Complication

Keywords

  • premedication
  • midazolam
  • opioids
  • remifentanil
  • Anesthesia, General
03

In context

Lead sponsor

Karaman Training and Research Hospital is the lead sponsor of 31 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • American Society of Anesthesiologists (ASA) class I and II patients
  • Patients who are scheduled for any elective surgery under general anesthesia

Exclusion criteria

Exclusion Criteria:

  • age \<18 or >60 years
  • current cervical spine disease or history of cervical spine surgery;
  • morbid obesity (body mass index, ≥35 kg/m2);
  • sleep apnea;
  • craniofacial anomaly;
  • allergic reaction to midazolam and remifentanil
  • chronic use of opioid, benzodiazepine, antipsychotic medications
  • pregnancy
  • presence of muscle weakness or dyspnea
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Group M

    Patients of the Group M will be treated with midazolam premedication.

    Drug: Midazolam

  • Placebo comparator
    Group S

    Group S patients are treated with 3 cc normal saline.

    Drug: Saline

Interventions

  • DrugMidazolam

    . Patients of the midazolam group will be treated with midazolam premedication (3 cc mixture of 0.035 mg/kg midazolam and normal saline; maximum midazolam dose, 3 mg) intravenously a waiting area 3 minutes before transportation to an operating room

    Also known as: Group M

  • DrugSaline

    Control group patients are treated with 3 cc normal saline in a waiting area 3 minutes before transportation to an operating room

    Also known as: Group S

06

What researchers measure

Primary outcomes

  1. Difficulty of mask ventilation (Warters grading scale 0-10)

    The difficulty of mask ventilation will be assessed after 30 seconds from propofol induction (loss of consciousness) with Warter's scale. The Warters scale assigns points based on escalating levels of intervention necessary to ventilate the lungs such as the use of an airway device, increased inspiratory pressure, and two-person ventilation, which are all intended to overcome upper airway resistance to ventilation. Additionally, the Warters scale accounts for situations in which a poor quality mask seal inhibits mask ventilation. Thus, in the event that the target tidal volume of 5 ml/kg is not achieved, and the provider is unable to generate a peak inspiratory pressure of \>30 cmH20, additional points are assigned. The scale is scored between 0-10 and higher scores indicate worse mask application.

    Time frame: During surgery at 30 seconds after loss of consciousness

Secondary outcomes

  1. Anxiety level; Numerical Rating Scale(NRS) score (0 - 10)

    The NRS is a segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0 to 10 integers) that best reflects the intensity of their anxiety (0= very calm, 10= very anxious).

    Time frame: One minute before the intervention in waiting area, and one minute before the anesthetic induction in operating room

  2. Sedation level (Modified Observer's assessment of alertness/sedation (MOAA/S) scale)

    Before the intervention in the waiting area, and before the anesthetic induction in the operating room sedation levels were evaluated with MOAA/S scale. The Modified Observer's Assessment of Alertness/Sedation (MOAA/S) Scale was developed to measure the level of alertness in subjects who are sedated. The Modified Observer's Assessment of Alertness and Sedation (MOAA/S) scale is frequently used in sedation-related drug and device studies to assess a subject's level of sedation. The MOAA/S ranges from 0 to 5, with a score of 5 defined as awake or minimally sedated, and a score of 0 defined as general anesthesia.

    Time frame: One minute before the intervention in waiting area, and one minute before the anesthetic induction in operating room

07

Study locations

1 site
  • Karaman Training and Research Hospital
    Karaman, Turkey
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05369819
Lead sponsor
Karaman Training and Research Hospital
Responsible party
Sponsor
First posted
May 11, 2022
Start date
May 24, 2022
Primary completion
Jan 2, 2024
Completion
Jan 3, 2024
Last update
Jan 5, 2024

Study contacts

Rafet Yarımoglu, MD
principal investigator · Karaman Training and Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion